Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

Bladder

Bladder
N/A
Arnold, Shanna
VICCURO1322

Neratinib HER Mutation Basket Study (SUMMIT)

Multiple Cancer Types

This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.
Bladder, Colon, Esophageal, Gastric/Gastroesophageal, Neuro-Oncology, Ovarian, Urologic, Uterine
II
Mayer, Ingrid
NCT01953926
VICCMD1403

Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and / or TSC2 Mutations

Bladder

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and / or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Bladder
II
Davis, Nancy
NCT03047213
VICCURO1723

Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy

Bladder

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles.
Bladder
I
Keegan, Kirk
NCT03404791
VICCURO17103

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: